This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Serdar Fak, A. Articles by Oktay, A. Search for Related Content PubMed Articles by Serdar Fak, A. Articles by Oktay, A. Social Bookmarking                         What's this?

Intravenous Propafenone for Conversion of Atrial Fibrillation or Flutter to Sinus Rhythm: A Randomized, Placebo-controlled, Crossover Study

Department of Cardiology, Marmara University School of Medicine

Hakan Tezcan

Department of Cardiology, Marmara University School of Medicine

Oguz Caymaz

Department of Cardiology, Marmara University School of Medicine

Sena Tokay

Department of Cardiology, Marmara University School of Medicine

ule Oktay

Department of Pharmacology, Marmara University School of Medicine, Istanbul, Turkey

Ahmet Oktay

Department of Cardiology, Marmara University School of Medicine

Background: Propafenone has been claimed to be effective in converting atrial fibrillation and flutter to sinus rhythm; however, controlled clinical trials have reported variable results, and data about the safety of propafenone in the setting of heart failure are lacking. The aim of the present study was to evaluate the efficacy and safety of intravenous propafenone in con verting atrial fibrillation and flutter to sinus rhythm.

Methods: Sixty patients with acute (< 72 h) or chronic atrial fibrillation or flutter were included in a randomized, placebo-controlled, conditional cross-over study. Twenty eight patients, of whom 12 were in New York Heart Association class III and IV, had heart failure. Patients received intravenous propafenone (2 mg/kg in 10 minutes) and placebo subsequently at 1 hour intervals if sinus rhythm was not achieved. The patients' rhythms were continuously monitored for 1 hour and a 12-lead electrocardiogram, a 1-minute continuous rhythm strip and vital signs were recorded at baseline and at 15, 30, 45, and 60 minutes after the adminis tration of each drug.

Results: Twenty of the 59 patients (34%) treated with propafenone converted to sinus rhythm, while only 4 of the 50 patients (8%) treated with placebo converted (P < .001). Propafenone was more effective in patients with acute (< 72 h) atrial fibrillation (64.5%). The conversion rate with propafenone was not significantly different from placebo in patients with atrial flutter and chronic atrial fibrillation (> 72 h). Propafenone significantly decreased (P < .005 vs placebo) mean ventricular rate in nonresponders with a baseline heart rate of more than 100 beats/min. No clinically significant adverse effect occurred.

Conclusions: We conclude that intravenous propafenone treatment is effective for converting acute atrial fibrillation; however, it seems unlikely to be beneficial in atrial flutter and chronic atrial fiorillation. Propafenone decreases ventricular rate in nonresponders, and a single dose of propafenone is relatively safe even in moderate-to-severe heart failure.

Key Words: propafenone • atrial fibrillation.

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 2, No. 4, 251-257 (1997)
DOI: 10.1177/107424849700200403


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?